C3 News

C3 celebrates 10th annual LGMD Awareness Day!

There is great strength in awareness, understanding, and unity. The LGMD community demonstrates global connectivity each year when we campaign together and gain recognition for LGMD. With over 30 different genetic types of LGMD, the act of collaborating globally makes

Published Research Alert: Atypical calcium handling in muscles of mouse model of LGMD2A/R1

Limb-Girdle Muscular Dystrophy 2A/R1 (LGMD2A/R1) is caused by changes in a gene called CAPN3, which provides instructions for making a protein called Calpain 3. This protein is specific to skeletal muscle and, among other functions, helps regulate calcium levels inside

Sarepta Therapeutics recruits for clinical outcomes assessment study

C3 is pleased to share this opportunity on behalf of Sarepta Therapeutics: Sarepta welcomes individuals with LGMD2A/R1 to join a clinical outcomes assessment study. To learn more about the study, visit journeyLGMD.com

New natural history study recruiting individuals with LGMD2A/R1 in France

Coalition to Cure Calpain 3 is pleased to share information regarding a natural history study being conducted in France. Patients must be affiliated with French social security to participate. Additional inclusion criteria is detailed in the flyer below. If you

Vita Therapeutics letter to the LGMD2A/R1 community

Today, Vita Therapeutics published an open letter to the LGMD2A/R1 community announcing some important changes to their development plans.

WATCH: Sarepta presents webinar about new natural history study for individuals living with LGMD2A/R1

Sarepta Therapeutics recently joined C3 to present a community webinar titled “Journey Update for the LGMD2A/R1 Calpainopathy Community.” During the webinar, Sarepta discussed the essential role for natural history studies throughout the drug development process. They then shared the design

Volker Straub appointed to C3 Scientific Advisory Board

Coalition to Cure Calpain 3 (C3) is pleased to share that Dr. Volker Straub has been appointed to our Scientific Advisory Board (SAB), joining Dr. Melissa Spencer (Chair), Dr. Kevin Campbell, Dr. Eric Hoffman, and Dr. Louis Kunkel. Professor Volker

C3 hosts Sarepta to present webinar about the JOURNEY natural history study

Click here to register!

C3 attends the 2024 MDA Clinical and Scientific Conference

The Muscular Dystrophy Association held their 2024 Clinical and Scientific Conference on March 3-6 in Orlando, Florida. C3 Scientific Director Dr. Jennifer Levy attended the meeting and shares the following highlights: The MDA Public Policy and Advocacy Team convened representatives

Trial readiness study for individuals with LGMD2A/R1

Please contact either Ruby Langeslay or Jennifer Raymond at Virginia Commonwealth University for more information